Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Cefazolin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 25, 2022
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit
Deal Size : Inapplicable
Deal Type : Inapplicable
Staphylococcus Aureus Network Adaptive Platform Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : ProvideGx
Deal Size : Undisclosed
Deal Type : Partnership
ProvideGx® Partners with Apotex to Stabilize Supply of Three Vital Antibiotics
Details : The three medicines include cefazolin, cefepime and ceftriaxone for injection and are part of the cephalosporin category of antibiotics. Cephalosporins are one of the most widely prescribed classes of medications in the world and treat a variety of bacte...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 02, 2021
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : ProvideGx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : University of Southern California
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 06, 2018
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : University of Southern California
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 18, 2018
Lead Product(s) : Cefazolin
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Physician Services Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Infections in Cardiac Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 06, 2014
Lead Product(s) : Cefazolin
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Physician Services Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 22, 2013
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable